shares of vir biotechnology inc vir were up 10 in trading on thursday after the company and glaxosmithkline gsk formally asked the food and drug administration to update the authorization for their covid19 treatment to include intramuscular administration gsks stock was up 01 after the news was announced the therapy sotrovimab is a monoclonal antibody used to treat some teens and adults who are at high risk for severe covid19 the therapy was originally authorized for singledose intravenous infusion virs stock is down 38 and gsk shares have gained 27 so far this year the sp 500 spx has declined 08